Novopharm And Wyeth-Ayerst Sign Deal
Wyeth-Ayerst of the USA will market around 200 products manufactured by the Canadian generics company Novopharm. Wyeth is to market the products under its own name, while Novopharm will also sell the products using its company name.
The deal means that Novopharm will be creating around 100 jobs in manufacturing at its Scarborough site in order to meet the demand for exports. The company has already embarked upon a C$15 million ($10.7 million) expansion at Scarborough, and is understood to be investing C$65 million in the construction of a factory in North Carolina in the USA.
Novopharm has annual sales of around C$500 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze